- $4.52m
- $14.20m
- $49.16m
- 23
- 60
- 11
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -116.19% | ||
| Return on Equity | -1620.81% | ||
| Operating Margin | -36.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 37.8 | 22.78 | 39.19 | 48.46 | 49.16 | 51.5 | 55.5 | 1.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.
Directors
- Jonathan Lord NEC (66)
- John Beaver PRE (59)
- Kathleen O'Loughlin DRC
- Martha Somerman DRC
- Carol Summerhays DRC
- Michael DiTolla IND (56)
- Richard Lanman IND (66)
- Jess Roper IND (56)
- Garrett Sato IND (60)
- Elaine Wagner IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 10th, 1987
- Public Since
- November 12th, 1992
- No. of Shareholders
- 11
- No. of Employees
- 157
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 32,522,593
- Address
- 27042 Towne Centre Drive, Suite 270, FOOTHILL RANCH, 92610
- Web
- https://www.biolase.com/
- Phone
- +1 9493611200
- Contact
- Michael Polyviou
- Auditors
- BDO USA, LLP
Upcoming Events for BIOL
BIOLASE Inc Annual Shareholders Meeting
Q1 2024 BIOLASE Inc Earnings Release
Q2 2024 BIOLASE Inc Earnings Release
Similar to BIOL
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the BIOLASE share price?
As of Today at 19:04 UTC, shares in BIOLASE are trading at $0.14. This share price information is delayed by 15 minutes.
How has the BIOLASE share price performed this year?
Shares in BIOLASE last closed at $0.14 and the price had moved by -99.54% over the past 365 days. In terms of relative price strength the BIOLASE share price has underperformed the S&P500 Index by -99.61% over the past year.
What are the analyst and broker recommendations for BIOLASE?
The overall consensus recommendation for BIOLASE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BIOLASE dividend yield?
BIOLASE does not currently pay a dividend.
Does BIOLASE pay a dividend?
BIOLASE does not currently pay a dividend.
When does BIOLASE next pay dividends?
BIOLASE does not currently pay a dividend.
How do I buy BIOLASE shares?
To buy shares in BIOLASE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BIOLASE?
As of the previous close price of $0.14, shares in BIOLASE had a market capitalisation of $4.52m.
Where are BIOLASE shares listed?
Here are the trading details for BIOLASE:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BIOL
What kind of share is BIOLASE?
Based on an overall assessment of its quality, value and momentum BIOLASE is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BIOLASE share price forecast for 2024?
The analyst consensus target price for shares in BIOLASE is $11.22. That is 7971.94% above the last closing price of $0.14.
Analysts covering BIOLASE currently have a consensus Earnings Per Share (EPS) forecast of -$0.32 for the next financial year.
What is the trend in the BIOLASE share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BIOLASE. Over the past six months, its share price has underperformed the S&P500 Index by -92.98%.
As of the last closing price of $0.14, shares in BIOLASE were trading -93.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BIOLASE PE Ratio?
The BIOLASE PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BIOLASE?
BIOLASE's management team is headed by:
- Jonathan Lord - NEC
- John Beaver - PRE
- Kathleen O'Loughlin - DRC
- Martha Somerman - DRC
- Carol Summerhays - DRC
- Michael DiTolla - IND
- Richard Lanman - IND
- Jess Roper - IND
- Garrett Sato - IND
- Elaine Wagner - IND